Skip to content

Author

S. Anguille

We have 2 of 184 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Inflammatory mechanisms in the AML bone marrow niche: From pathogenesis to therapy.

This review summarizes the current knowledge on inflammatory cytokines and signaling pathways in AML, focusing on their mechanisms of action and implications for immune tolerance and clonal hematopoiesis and the emerging therapeutic strategies targeting these pathways to improve clinical outcomes for patients with AML.

Toon Suls, E. Lion, Florian Van Oers et al. · 0 citations
Clinical trial Sep 2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

This phase 1 dose-escalation part of the ATALANTA-1 phase 1/2, single-arm study was executed in five hospitals in the Netherlands and Belgium to evaluate the safety and determine the recommended phase 2 dose of GLPG5101.

M. Kersten, M. Kuipers, P. Mutsaers et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.